Zealand Pharma A/S (Zealand Pharma A/S) Research & Development : $106.48 Mil (TTM As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Zealand Pharma A/S's Research & Development for the three months ended in Mar. 2024 was $27.83 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was $106.48 Mil.

Zealand Pharma A/S Research & Development Historical Data

The historical data trend for Zealand Pharma A/S's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Research & Development Chart

Zealand Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

Get a 7-Day Free Trial

83.51

97.43

88.36

87.44

100.21

Zealand Pharma A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Research & Development	Get a 7-Day Free Trial															20.46	22.64	28.18	27.83	27.83

Zealand Pharma A/S Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $106.48 Mil.

Zealand Pharma A/S (OTCPK:ZLDPF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Zealand Pharma A/S Research & Development Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OTCPK:ZLDPF) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

ZEALc:UK 0NZU:UK ZEAL:Denmark 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.